CONTACT
DIAGNOSTICS
ABOUT ABBOTT
i-STAT Registration
i-STAT Login
CUSTOMER HOME
PARTNERS HOME
DISTRIBUTION HOME
EMPLOYEES HOME
REPAIR MANUAL
COMPLETE PROFILE
DASHBOARD
My Account
United States

Global Point of Care

OBJECTIVELY
ASSESS MILD TBI

AT THE POINT OF CARE

The i-STAT TBI cartridge* is the first point-of-care venous whole blood test for mild TBI that measures brain-specific biomarkers and delivers objective data in 15 minutes.1

Contact Us
*Available only on the i-STAT Alinity instrument | TBI=traumatic brain injury
background image background image background image

OBJECTIVELY ASSESS
MILD TBI

AT THE POINT OF CARE

The i-STAT TBI cartridge* is the first point-of-care venous whole blood test for mild TBI that measures brain-specific biomarkers and delivers objective data in 15 minutes.1

Contact Us
*Available only on the i-STAT Alinity instrument | TBI=traumatic brain injury
Chapter Navigation

PEER TO PEER: OVERCOMING CHALLENGES WITH MILD TBI ASSESSMENTS

Emergency department (ED) physician Chris Davlantes shares his insights about the challenges in obtaining accurate mild TBI assessments—and how a new assessment tool can help you more objectively and accurately assess your patients at the point of care.
 

SELECT AN IMAGE TO VIEW VIDEO
<h4><span style=" color: rgb(0,79,113); ">ASSESSING CHALLENGING<br /> TBI CASES</span></h4>

ASSESSING CHALLENGING
TBI CASES

Dr. Davlantes discusses the types of cases he sees in his ED that present challenges to assessing possible head injury at the point of care.

<h4><span style=" color: rgb(0,79,113); ">OVERCOMING BARRIERS<br /> OF CT</span></h4>

OVERCOMING BARRIERS
OF CT

Even if access to radiology is readily available, certain factors in the Emergency Department can complicate the decision to order a head CT.

<h4><span style=" color: rgb(0,79,113); ">THE RISK OF PROLONGED OBSERVATION</span></h4>

THE RISK OF PROLONGED OBSERVATION

The story of an altered patient under observation in a busy ED serves as a wake-up call for the need to objectively prioritize head trauma cases.

MEASURING BIOMARKERS ENABLES OBJECTIVE ASSESSMENT
OF PATIENTS WITH SUSPECTED MILD TBI1-5

GFAP and UCH-L1 are well-validated, complementary, brain-specific biomarkers released into the bloodstream from two different cell types following traumatic brain injury.1

GFAP

GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP)

  • GFAP is a specific marker of astrocyte injury in either white or gray matter that is elevated in patients with traumatic intracranial abnormalities on CT1,4
  • GFAP reliably distinguishes between trauma patients with mild traumatic brain injury (mTBI) and those without head injury5
  • Unlike some previously studied biomarkers, GFAP levels are not affected by extracranial trauma or exercise6-9

UCH-L1

UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L1 (UCH-L1)

  • UCH-L1 is a degradation enzyme highly and exclusively expressed in neurons10
  • Blood levels have been demonstrated to distinguish mTBI patients from those without injuries11

MEASURING BIOMARKERS ENABLES OBJECTIVE ASSESSMENT 

OF PATIENTS WITH SUSPECTED MILD TBI1-5

GFAP and UCH-L1 are well-validated, complementary, brain-specific biomarkers released into the bloodstream from two different cell types following traumatic brain injury.1

GFAP

GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP)

  • GFAP is a specific marker of astrocyte injury in either white or gray matter that is elevated in patients with traumatic intracranial abnormalities on CT1,4
  • GFAP reliably distinguishes between trauma patients with mild traumatic brain injury (mTBI) and those without head injury5
  • Unlike some previously studied biomarkers, GFAP levels are not affected by extracranial trauma or exercise6-9

UCH-L1

UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L1 (UCH-L1)

  • UCH-L1 is a degradation enzyme highly and exclusively expressed in neurons10
  • Blood levels have been demonstrated to distinguish mTBI patients from those without injuries11

RELIABLE 24-HOUR TESTING WINDOW FROM THE COMPLEMENTARY KINETICS OF GFAP AND UCH-L11,2

infographic infographic
biomarkers biomarkers

When both GFAP and UCH-L1 are 'Not Elevated', this is associated with the absence of acute traumatic intracranial lesions that would be visualized on a head CT scan.1 

*When either biomarker is elevated, further clinical evaluation and CT should still be considered.
The i-STAT TBI cartridge is not intended as a stand-alone assessment tool, but as an adjunct to other clinical information to aid in the evaluation of patients who are being considered for standard-of-care neuroimaging.

INNOVATIONS IN PATIENT CARE

What impact will the i-STAT TBI cartridge have on your patients and care team? Contact us and explore our innovative, point-of-care products that deliver lab-quality results in minutes.

contact us
i-STAT TBI
i-STAT ALINITY
background image background image

INNOVATIONS IN PATIENT CARE

What impact will the i-STAT TBI cartridge have on your patients
and care team?

contact us
i-STAT TBI
i-STAT ALINITY
ADDITIONAL RESOURCES
Biomarkers in Assessing mTBI

This white paper explains more about the role biomarkers play in the assessment of mild traumatic brain injury.

Read Paper
biomarker

Explore the science behind the evaluation of traumatic brain injury through this web site's articles, videos and related content.

Visit Site
Biomarkers in Assessing mTBI

Discover more on the role of biomarkers (GFAP and UCH-L1) in assessing mild traumatic brain injury (mTBI).

View Video

REFERENCES

  1. i-STAT TBI cartridge. Instructions for use. Abbott Point of Care Inc. Abbott Park, IL; 2024.
  2. Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 2016;12(10):563-574.
  3. Chodobski A, Zink BJ, Symydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011;2(4):492-516.
  4. Metting Z, Wilczak N, Rodiger LA, et al. GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology. 2012;78(18):1428-1433.
  5. Papa L, Lewis LM, Falk JL, et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med. 2012;59(6):471-483.
  6. Jones A, Jarvis P. Review of the potential use of blood neuro-biomarkers in the diagnosis of mild traumatic brain injury. Clin Exp Emerg Med. 2017;4(3):121-127.
  7. Schulte S, Podlog LW, Hamson-Utley JJ, et al. A systematic review of the biomarker S100B: implications for sport-related concussion management. J Athl Train. 2014;49(6):830-850.
  8. Steiner J, Bernstein H-G, Bielau H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 2007;8:2.
  9. Pelinka LE, Kroepfl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma. 2004;57(5):1006-1012.
  10. Diaz-Arrastia R, Wang KKW, Papa L, et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma. 2014;31(1):19-25.
  11. Papa L, Lewis LM, Silvestri S, et al. Serum levels of ubiquitin C-terminal hydrolase (UCH-L1) distinguish mild traumatic brain injury (TBI) from trauma controls and are elevated in mild and moderate TBI patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg. 2012;72(5):1335-1344.
  12. Papa L, Brophy GM, Welch RD, et al. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 2016;73(5):551-560.

a leader in rapid point-of-care diagnostics.

PRODUCT CATALOG
SOLUTIONS
CUSTOMER STORIES
VIEWPOINTS
TOXICOLOGY
CONTACT US
PRODUCT DOCUMENT SEARCH
PRODUCT DEMOS
INTEREST-BASED ADS
CONSUMER HEALTH DATA PRIVACY POLICY

©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement

Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.

Abbott - A Leader in Rapid Point-of-Care Diagnostics.